(Q30595175)

English

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1 reference

based on heuristic

inferred from title

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Alessandra Larocca

object named as

Alessandra Larocca

4

0 references

Vittorio Montefusco

object named as

Vittorio Montefusco

23

0 references

Roberto Marasca

object named as

Roberto Marasca

18

0 references

Massimo Offidani

object named as

Massimo Offidani

11

0 references

object named as

Roberto Ria

10

0 references

Giovannino Ciccone

object named as

Giovannino Ciccone

24

0 references

object named as

Albert Oriol

6

0 references

Jesús San Miguel

object named as

Jesus San Miguel

26

0 references

Pieter Sonneveld

27

object named as

Pieter Sonneveld

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Antonio Palumbo

28

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

3

object named as

Sonja Zweegman

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Bronno van der Holt

22

object named as

Bronno van der Holt

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Luca Franceschini

19

object named as

Luca Franceschini

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1

object named as

Sara Bringhen

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Juan José Lahuerta

12

object named as

Juan Jose Lahuerta

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Mario Boccadoro

25

object named as

Mario Boccadoro

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Ana-Isabel Teruel

21

object named as

Ana-Isabel Teruel

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

María Victoria Mateos

2

object named as

Maria Victoria Mateos

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Débora Andréa Evangelista Façanha

20

object named as

Andrea Evangelista

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

8

object named as

Maide Cavalli

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Pierre Wijermans

9

object named as

Pierre Wijermans

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Anna Marina Liberati

13

object named as

Anna Marina Liberati

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Martijn Schaafsma

16

object named as

Martijn Schaafsma

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

17

object named as

Chiara Cerrato

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Antonietta Pia Falcone

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Davide Rossi

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Roberto Mina

14

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Vincenzo Callea

15

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

publication date

26 February 2013

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

98

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

980-987

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Aging and pharmacology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Pharmacology of cancer chemotherapy in the older person.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Altered pharmacokinetics in the elderly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

14 July 2018

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Thalidomide in patients with multiple myeloma and renal failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669456

26 November 2018

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions

1 reference

https://pubmed.ncbi.nlm.nih.gov/23445873

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age is not a prognostic variable with autotransplants for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23445873

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://pubmed.ncbi.nlm.nih.gov/23445873

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23445873

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23445873

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

https://pubmed.ncbi.nlm.nih.gov/23445873

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2012.075051

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

release_gie4ilbzw5gkdhlwg2orxhps7m

1 reference

https://api.fatcat.wiki/v0/release/gie4ilbzw5gkdhlwg2orxhps7m

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30595175&oldid=1858320722"